United Advisor Group LLC Sells 7,285 Shares of Bristol Myers Squibb Company (NYSE:BMY)

United Advisor Group LLC decreased its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 35.7% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 13,106 shares of the biopharmaceutical company’s stock after selling 7,285 shares during the quarter. United Advisor Group LLC’s holdings in Bristol Myers Squibb were worth $799,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Wealthspire Advisors LLC increased its holdings in shares of Bristol Myers Squibb by 0.6% during the 4th quarter. Wealthspire Advisors LLC now owns 28,679 shares of the biopharmaceutical company’s stock worth $1,622,000 after buying an additional 170 shares during the last quarter. Bedel Financial Consulting Inc. grew its position in Bristol Myers Squibb by 3.2% in the fourth quarter. Bedel Financial Consulting Inc. now owns 5,690 shares of the biopharmaceutical company’s stock worth $340,000 after acquiring an additional 175 shares during the period. King Wealth Management Group increased its stake in Bristol Myers Squibb by 2.6% during the fourth quarter. King Wealth Management Group now owns 7,294 shares of the biopharmaceutical company’s stock worth $413,000 after acquiring an additional 182 shares during the last quarter. Thoroughbred Financial Services LLC increased its position in shares of Bristol Myers Squibb by 1.1% during the 4th quarter. Thoroughbred Financial Services LLC now owns 17,763 shares of the biopharmaceutical company’s stock worth $1,004,000 after purchasing an additional 190 shares during the last quarter. Finally, Marcum Wealth LLC lifted its position in Bristol Myers Squibb by 1.0% in the first quarter. Marcum Wealth LLC now owns 19,296 shares of the biopharmaceutical company’s stock valued at $1,177,000 after buying an additional 193 shares during the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

Insider Activity at Bristol Myers Squibb

In related news, EVP Samit Hirawat purchased 4,250 shares of Bristol Myers Squibb stock in a transaction on Friday, April 25th. The stock was bought at an average price of $47.58 per share, with a total value of $202,215.00. Following the completion of the transaction, the executive vice president now directly owns 83,513 shares of the company’s stock, valued at approximately $3,973,548.54. This represents a 5.36% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.09% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

BMY has been the topic of a number of research reports. Cantor Fitzgerald reiterated a “neutral” rating and set a $55.00 target price on shares of Bristol Myers Squibb in a report on Tuesday, April 22nd. Piper Sandler began coverage on Bristol Myers Squibb in a research note on Tuesday, April 22nd. They issued an “overweight” rating and a $65.00 price target on the stock. Argus raised Bristol Myers Squibb to a “hold” rating in a research report on Friday, April 25th. Jefferies Financial Group dropped their price objective on Bristol Myers Squibb from $70.00 to $68.00 and set a “buy” rating on the stock in a report on Wednesday, April 23rd. Finally, UBS Group decreased their target price on Bristol Myers Squibb from $60.00 to $54.00 and set a “neutral” rating for the company in a research note on Friday, April 11th. Two research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Bristol Myers Squibb currently has an average rating of “Hold” and a consensus price target of $58.00.

Bristol Myers Squibb Stock Down 0.9%

Bristol Myers Squibb stock opened at $46.82 on Thursday. Bristol Myers Squibb Company has a twelve month low of $39.35 and a twelve month high of $63.33. The company has a debt-to-equity ratio of 2.65, a quick ratio of 1.17 and a current ratio of 1.28. The firm has a market cap of $95.29 billion, a PE ratio of 17.54, a P/E/G ratio of 1.39 and a beta of 0.38. The firm’s 50 day moving average price is $48.35 and its two-hundred day moving average price is $54.52.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, topping analysts’ consensus estimates of $1.50 by $0.30. The business had revenue of $11.20 billion for the quarter, compared to the consensus estimate of $10.77 billion. Bristol Myers Squibb had a net margin of 11.38% and a return on equity of 87.62%. Bristol Myers Squibb’s revenue for the quarter was down 5.6% compared to the same quarter last year. During the same period in the prior year, the business posted ($4.40) earnings per share. On average, research analysts predict that Bristol Myers Squibb Company will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, August 1st. Stockholders of record on Thursday, July 3rd will be issued a dividend of $0.62 per share. The ex-dividend date is Thursday, July 3rd. This represents a $2.48 annualized dividend and a dividend yield of 5.30%. Bristol Myers Squibb’s dividend payout ratio is 92.88%.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.